VRTX

VERTEX PHARMACEUTICALS INC

Apr 05 • 04:00PM ET

438.65

+4.27 (+0.98%)

Company Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of si ... read more

Full Time Employees 5,400

Phone 617 341 6100

Website https://www.vrtx.com

CEO Dr. Reshma Kewalramani FASN, M.D.

IPO Date 1991-07-24

Sector Healthcare

Industry Biotechnology

Address 50 Northern Avenue, Boston, MA 02210

Balance Sheet

Total Cash $4,674,700,000

Total Debt $1,649,100,000

Current Ratio 2.65

Quick Ratio 2.12

Profitability

Gross Margin 86.03%

Net Margin -8.91%

ROE -5.99%

ROA -4.32%

ROIC -13.44%

Balance Sheet

Total Cash $4,674,700,000

Total Debt $1,649,100,000

Current Ratio 2.65

Quick Ratio 2.12

Profitability

Gross Margin 86.03%

Net Margin -8.91%

ROE -5.99%

ROA -4.32%

ROIC -13.44%

Name	VERTEX PHARMACEUTICALS INC	Sector	Healthcare	Currency	USD	Relative Volume	1.93	Market Cap	121877
Current Ratio	2.69	Dividend / Share	0.0	EPS	-2.08	Revenue	11020100000	P/S	11.1
P/E	-227.6	Beta	0.51	Income	-535600000	Volume	2879948	Average Volume	1494114
Distance to 200DMA	0.91%	200 DMA	470.34	50 DMA	481.15	ROA	-2.4	ROE	-3.3
Distance to 50DMA	-1.36%	Return 1Y	16.1%	Return YTD	17.86%	Forward PE		Qtly Growth YOY
Debt/Eq	0.37	P/B	7.4	Dividend Yield	0.0%	Net Margin	-4.86%	Payout Ratio	0.0

Performance

52 Week Range 0.0%

Distance to 200DMA 0.0%

Day Change Percent $0.00

Performance Range

Day

$196

Current

Low: High:

Month

$196

Current

Low: High:

Month

$196

Current

Low: High:

Month

$196

Current

Low: High:

Month

$196

Current

Low: High:

Balance Sheet

Total Cash $5,239,200,000

Total Debt $1,702,900,000

Current Ratio 2.47%

Quick Ratio 1.76%

Profitability

Valuation

Price to Earnings -113.95

Price to Book 6.83

Price to Sales 10.15

Price to Free Cash Flow -90.13

Dividends

Payout Ratio -0.00%

Dividend Yield 0.00%

Dividend Amount $0.00

Performance

52 Week Range 0.0%

Distance to 200DMA 0.0%

Day Change Percent $0.00

Company Profile

Full Time Employees 5,400

Phone 617 341 6100

Website https://www.vrtx.com

CEO Dr. Reshma Kewalramani FASN, M.D.

IPO Date 1991-07-24

Sector Healthcare

Address 50 Northern Avenue, Boston, MA 02210

Histogram - Daily

Balance Sheet

Total Cash $5,239,200,000

Total Debt $1,702,900,000

Current Ratio 2.47%

Quick Ratio 1.76%

Profitability

Gross Margin 0.8610%

Net Margin -0.0450%

ROE -0.03%

ROA -0.02%

Company Profile

Full Time Employees 5,400

Phone 617 341 6100

Website https://www.vrtx.com

CEO Dr. Reshma Kewalramani FASN, M.D.

IPO Date 1991-07-24

Sector Healthcare

Address 50 Northern Avenue, Boston, MA 02210

Monthly Win Rate

Balance Sheet (Multi-Column Example)

	Dec 2024	Sep 2024	Jun 2024	Mar 2024	Dec 2023	Sep 2023	Jun 2023	Mar 2023
Cash & Short Term Investments	53,775.0	65,171.0	61,801.0	67,150.0	73,100.0	61,555.0	62,482.0	55,872.0
Receivables	59,306.0	66,243.0	43,172.0	41,150.0	50,102.0	60,985.0	39,186.0	35,899.0
Inventory	6,911.0	7,286.0	6,165.0	6,232.0	6,511.0	6,331.0	7,351.0	7,482.0

Latest News

Vertex to Participate in Upcoming Investor Conferences

BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced management participation in three upcoming investor conferences. Susie Lisa, Senior Vice President, Investor

2025-05-15 16:05:00 - businesswire.com

Best Biotech Stocks to Buy in 2025

The bear market induced by the Federal Reserve's monetary tightening officially ended in 2023, but it seems no one remembered to tell the biotech sector.

2025-05-13 08:10:10 - marketbeat.com

2 Biotech Stocks That Are Screaming Buys in May

It's very tempting to pile into the stocks with the strongest positive momentum of the moment -- they've proven themselves and could continue along this path. But in many cases, you could set yourself

2025-05-13 07:10:00 - fool.com

This Stock Just Dropped by 12% in 1 Day. History Says This Will Happen Next

Vertex Pharmaceuticals (VRTX 3.40%), a leading drugmaker, is performing exceedingly well for the year -- or at least it was, until it released its first-quarter update. The results were not to the mar

2025-05-13 04:52:00 - fool.com

Prediction: These 2 Stocks Will Outperform the Market in the Next Five Years

Regardless of how stocks are performing right now, history tells us that the market tends to generate solid returns over long periods. Investors can do even better than the average market performance

2025-05-12 07:08:00 - fool.com

My Favorite Tariff Safe-Haven Stock to Buy on the Dip

Uncertainty has weighed on stocks over the past several weeks, pushing the three major indexes lower -- the S&P 500 (^GSPC -0.07%) even temporarily slid into a bear market. What's driven this negative

2025-05-10 04:12:00 - fool.com

Final Trades: Vertex Pharma, Palantir, Wynn Resorts and Microsoft

The Investment Committee give you their top names to watch for the second half.

2025-05-09 13:38:58 - youtube.com

Vertex Pharmaceuticals Incorporated (VRTX) is Attracting Investor Attention: Her

Recently, Zacks.com users have been paying close attention to Vertex (VRTX). This makes it worthwhile to examine what the stock has in store.

2025-05-09 10:06:07 - zacks.com

4 No-Brainer Stocks to Buy Right Now

Market volatility and near-term uncertainty can be challenging to deal with these days -- or at any time. However, even in the current environment, there are excellent investment opportunities.

2025-05-09 06:30:00 - fool.com

VRTX Stock Down as Q1 Sales of New Drugs Miss Expectations

Sales from VRTX's new drugs, Casgevy, Alyftrek and Journavx, in Q1 fell short of investor expectations.

2025-05-07 08:30:35 - zacks.com

Why Vertex Pharmaceuticals Stock Is a Screaming Buy on the Dip

Vertex Pharmaceuticals' (VRTX -9.39%) remarkable momentum came to a screeching halt this week. The big biotech stock had been up well over 20% year to date.

2025-05-07 04:49:00 - fool.com

Why Did Vertex Pharmaceuticals Stock Fall On Tuesday?

On Monday, Vertex Pharmaceuticals Incorporated VRTX reported lower-than-expected first-quarter 2025 earnings.

2025-05-06 16:28:44 - benzinga.com

VRTX's Q1 Earnings Lag Estimates, 2025 Revenue View Tightened

Vertex reports weaker-than-expected first-quarter 2025 results. The company tightens its total revenue guidance for 2025.

2025-05-06 13:00:38 - zacks.com

Vertex Pharmaceuticals Stock Is Tumbling After Earnings. Here's Why.

The company discloses narrower-than-expected access to its new painkiller.

2025-05-06 12:31:00 - barrons.com

Top Stock Movers Now: Vertex, DoorDash, Constellation Energy, and More

U.S. equities were lower at midday as the market watched for any possible deals involving Trump administration tariffs and awaited tomorrow's statement from the Federal Reserve policymakers following

2025-05-06 12:06:09 - investopedia.com

2 Pharma Stocks Staging Big Post-Earnings Moves

Biopharmaceutical giants Vertex Pharmaceuticals Inc (NASDAQ:VRTX) and Neurocrine Biosciences Inc (NASDAQ:NBIX) are fresh out of the earnings confessional, with very different results.

2025-05-06 10:43:39 - schaeffersresearch.com